The OTC markets offer a veritable treasure trove of stocks if one can put in diligent research and learn about the companies worthy of tracking. This feature provides a detailed look at a few companies that could be possible additions to any savvy investor’s watchlist. Let’s take a closer look and find out why!
Ameritek Ventures (OTC:ATVK): ATVK continues to experience positive momentum in the market as a leading provider of software and hardware products to businesses, organizations, and governments. The emerging technology provider offers various software and hardware products and services through several subsidiaries specializing in specific sectors.
FlexFridge, the company’s subsidiary, continues to strengthen the company’s prospects and edge in the medical industry with its flagship FlexFridge portable medical-use smart mini fridge. The fridge comes with an 8-hour battery life, making it ideal for transporting vaccines and medicines requiring below-freezing temperatures.
DittoMask is another subsidiary that is strengthening the company’s prospects in pursuit of growth opportunities in the sports industry. The unit develops custom-fit masks that offer durable protection against dust, smoke, pollen, and small particles. The masks continue to elicit strong demand from individuals with active lifestyles, including athletes and outdoor enthusiasts, due to their breathable polyester adjustable straps and ease of cleaning and reuse.
In addition, Ameritek Venture is pursuing opportunities for growth around emerging technologies. Augmum is the company’s unit focused on augmented reality technology. The company already leverages technology and machine learning systems to control robot arms with gloves and glasses. Additionally, Augmum has already created motion-tracking robotic hands, touch-sensing gloves, and virtual reality glasses that could elicit strong interest from various industries.
“We are excited to be offering HailOasTM to our customers. It is a high-quality and affordable AR solution that can enhance their experience with our AI-integrated robotic arm technology,” said Shaun Passley, Ph.D., CEO of Ameritek Ventures, Inc.
The AR glasses are designed to enable people to interact with a robotic arm more intuitively and immersively while accessing various applications and features that can improve their productivity and efficiency. Priced at less than $500, the glasses could be a game-changer in democratizing and enhancing access to crucial augmented reality glasses. Currently, most people are forced to pay as much as $3,500 to acquire augmented reality glasses, something that Ameritek Ventures is looking to change and tap into the massive market opportunity.
Additionally, Ameritek Ventures is looking to take advantage of the artificial intelligence boom; its wholly-owned subsidiary, ESM Software, has released its Business Decision Making product. The artificial intelligence-powered solution will allow users to leverage data-driven insights, automate processes, and optimize resources, thereby enjoying improved outcomes.
These AI-powered solutions add to the company’s performance management software and service to help organizations formulate, implement measures, and improve business strategy. The solution is already being used to offer balanced scorecards and employee performance appraisals.
Elite Pharmaceuticals Inc. (OTC: ELTP): Elite Pharmaceuticals Inc. is a specialty pharmaceutical firm involved in the manufacturing, development, and distribution of specialized generic products. The company’s product lines are made up of both controlled-release and immediate-release solid orally administered products.
The products are marketed by the company under the Elite Laboratories label and also as per the licenses that are granted by the company to third-party pharmaceutical distribution and marketing organizations.
On August 14, the company announced its financial results for the first fiscal quarter of 2024, which ended on June 30, 2023.
The consolidated revenues generated by Elite Pharmaceuticals for the quarter were $9 million, which reflected a year-on-year rise of 16.9%, or $1.3 million, from the corresponding period in the prior year. The company’s operating profits stood at $1.6 million, which worked out to a year-on-year rise of 60% or $1.6 million.
The net income attributable to shareholders for the quarter was $1.1 million, which worked out to a year-on-year rise of 267%, or $0.8 million, from the prior-year period. The stronger performance in the quarter was mainly a function of higher revenues from manufacturing activities that had been clocked through the launch of the product lines from Elite Laboratories in the quarter.
EBET Inc. (OTC: EBET): is involved in the development and operations of i-gaming wagering products for bettors worldwide. It is focused on offering improved i-gaming products to the market that fulfill the needs of Gen-Z and millennial customers in the betting space. On July 26, the company announced that its Board of Directors had decided to launch a process for the purpose of exploring new strategic alternatives so that the value of EBET’s portfolio could be maximized.
In order to put the process into motion, the company put a Strategic Alternatives Committee in place. At the time, it was noted that the committee would be responsible for helping the board with a range of alternatives that may include a sale, a potential merger, and other strategic transactions.
Aaron Speach, EBET’s Chief Executive Officer, commented, “After a detailed evaluation, we have determined to launch a formal review of our strategic options to determine which alternative or alternatives are the best path to maximize value. The EBET team remains fully committed to meeting the needs of our customers by continuing to provide them with an exceptional gaming experience”.
The company also retained the services of Houlihan Lokey as its exclusive financial advisor to provide guidance in the review process. The Chief Executive Officer of the company, Aaron Speach, spoke about the move as well. He noted that EBET had conducted a thorough evaluation and had determined that it had then decided to start the formal review of its strategic options so as to determine the best path forward that would maximize value. He went on to add that amidst everything, the company remained committed to providing its customers with the best gaming experience on the market.
However, the company also added in its news release that there was no guarantee that the strategic review was going to necessarily lead to the discovery of any alternative. There were no assurances about the outcome of the process or its timing, either. EBET noted that no timeline had been set for the completion of the process, and there were no plans to provide updates with regards to its progress until and unless a definitive agreement had been executed.
Enzolytics Inc. (OTC: ENZC): is a drug development company that is involved in the commercialization of its proprietary proteins and monoclonal antibodies for treating impairing infectious diseases. The company has a subsidiary unit named Biogenysis, which deploys proprietary techniques for the production of fully human monoclonal antibodies targeting infectious diseases.
On August 24, Biogenysis announced that there had been progress in its Patent Cooperation Treaty (PCT) application that encompassed its inventions in relation to anti-SARS-CoV-2 monoclonal antibodies. The company revealed that the PCT application had progressed to the stage of filing a United States National Stage Application in the United States Patent Office. Additionally, there had been a formal application to the European Patent Organization (EPO) as well.
Gaurav Chandra, Biogenysis’ CEO, stated, “Amid alarming concerns regarding COVID mutations, it is crucial to prioritize efforts towards achieving broader immunity against variants, longer-lasting protection, and preventing infection and transmission. Utilizing intranasal IgA monoclonal antibodies effectively attains high secretory IgA levels, reflecting mucosal immunity. The Biogenysis anti-COVID monoclonal antibodies, both IgG and IgA, being universal, broadly neutralizing, durable, and unaffected by mutations, are a critical solution to this pressing issue.”
The EPO would provide coverage for the PCT in as many as 39 nations. It includes all the nations in the European Union, the United Kingdom, and other nations across Europe and nearby regions. The pending applications from the company make up a total of 23 different patent claims. It was further revealed that, through the deployment of artificial intelligence, it had been possible for Biogenysis to discover a total of 19 immutable conserved virus sites on the COVID-19 virus.
The company had succeeded in making the discovery through the analysis of 2.8 million isolates of SARS-CoV-2. The sites discovered by the company were patentable due to their unique specificity and the discovery that they were conserved on SARS-CoV-2.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Ameritek Ventures Inc. to assist in the production and distribution of content. ‘CGR’ is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.